Transrectal ultrasound and needle biopsy of the prostate
Abstract
In the last 25 years widespread use of prostatic specific antigen caused a stage migration of prostate cancer towards localized disease at diagnosis, which resulted in transrectal ultrasound biopsy to become standard in clinical practice. Transrectal ultrasound examination of the prostate is used to diagnose benign prostatic diseases, e.g. benign prostatic enlargement, prostatitis, prostatic and seminal vesicle cysts. It is also important in detection of obstructive causes of male infertility. Transrectal ultrasound examination is performed most often in needle biopsy for prostate cancer diagnosis. Besides guiding systematic tissue core biopsy, characteristic ultrasound changes enables target biopsies of suspect areas. The article describes indications, contraindications, antibiotic prophylaxis, various biopsy templates and complications of the needle biopsy. Experience with transrectal ultrasound guided biopsy at Department of urology at University medical center in Ljubljana is presented.
Downloads
References
Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. European journal of cancer. 2015;51(9):1164-1187.
SLORA: Slovenija in rak. Epidemiologija in register raka. Onkološki inštitut Ljubljana; 2011. www.slora.si (05.10.2015).
Stattin P, Johansson R, Damber JE, et al. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry. Scandinavian journal of urology and nephrology. 2003;37(6):461-465.
Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. The New England journal of medicine. 2012;366(11):981-990.
Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. Journal of the National Cancer Institute. 2012;104(2):125-132.
Kilpelainen TP, Tammela TL, Malila N, et al. Prostate cancer mortality in the Finnish randomized screening trial. Journal of the National Cancer Institute. 2013;105(10):719-725.
Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. European urology. 2011;59(1):61-71.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. The New England journal of medicine. 1987;317(15):909-916.
Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. The Cochrane database of systematic reviews. 2013;1:CD004720.
Watanabe H, Kato H, Kato T, Morita M, Tanaka M. Diagnostic application of ultrasonotomography to the prostate. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology. 1968;59(4):273-279.
Hodge KK, McNeal JE, Stamey TA. Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. The Journal of urology. 1989;142(1):66-70.
Trabulsi EJ, Halpern EJ, Gomella LG. Ultrasonography and biopsy of the prostate. In: Wein AJ, Kavoussi LR, Campbell MF, eds. Campbell-Walsh urology. Vol 3. 10th ed. Philadelphia, PA: Elsevier Saunders; 2012:2735-2747.
Stravodimos KG, Petrolekas A, Kapetanakis T, et al. TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up? International urology and nephrology. 2009;41(4):767-771.
Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European urology. 2013;64(1):118-140.
Vyas JB, Ganpule SA, Ganpule AP, Sabnis RB, Desai MR. Transrectal ultrasound-guided aspiration in the management of prostatic abscess: A single-center experience. The Indian journal of radiology & imaging. 2013;23(3):253-257.
Chou YH, Tiu CM, Liu JY, et al. Prostatic abscess: transrectal color Doppler ultrasonic diagnosis and minimally invasive therapeutic management. Ultrasound in medicine & biology. 2004;30(6):719-724.
Grabe M, Bartoletti R, Bjerklund-Johansen TE, et al. Guidelines on urological infections EAU Guidelines, edition presented at the 29th EAU Annual Congress. Stockholm2014.
Shebel HM, Farg HM, Kolokythas O, El-Diasty T. Cysts of the lower male genitourinary tract: embryologic and anatomic considerations and differential diagnosis. Radiographics : a review publication of the Radiological Society of North America, Inc. 2013;33(4):1125-1143.
Lee F, Gray JM, McLeary RD, et al. Transrectal ultrasound in the diagnosis of prostate cancer: location, echogenicity, histopathology, and staging. The Prostate. 1985;7(2):117-129.
Shinohara K, Wheeler TM, Scardino PT. The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. The Journal of urology. 1989;142(1):76-82.
Ganie FA, Wanie MS, Ganie SA, et al. Correlation of transrectal ultrasonographic findings with histo pathology in prostatic cancer. Journal of education and health promotion. 2014;3:38.
Noh TI, Shin YS, Shim JS, et al. Are hypoechoic lesions on transrectal ultrasonography a marker for clinically significant prostate cancer? Korean journal of urology. 2013;54(10):666-670.
Ezquer A, Ortega Hrescak MC, Sanagua C, et al. Transrectal doppler ultrasound during prostate biopsy: Clinical utility and limitations. Actas urologicas espanolas. 2015 ;39(1):13-9.
Sharma S. Imaging and intervention in prostate cancer: Current perspectives and future trends. The Indian journal of radiology & imaging.2014;24(2):139-148.
Zaleska-Dorobisz U, Kaczorowski K, Pawlus A, Puchalska A, Inglot M. Ultrasound elastography - review of techniques and its clinical applications. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2014;23(4):645-655.
Sparks R, Bloch BN, Feleppa E, Barratt D, Madabhushi A. Fully Automated Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Fusion via a Probabilistic Registration Metric. Proceedings - Society of Photo-Optical Instrumentation Engineers.2013;8671.
Peltier A, Aoun F, El-Khoury F, et al. 3D versus 2D Systematic Transrectal Ultrasound-Guided Prostate Biopsy: Higher Cancer Detection Rate in Clinical Practice. Prostate cancer. 2013;2013:783243.
Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. Jama.2003;289(20):2695-2700.
Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. European urology. 2010;57(1):79-85.
Sabbagh R, McCormack M, Peloquin F, et al. A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy. The Canadian journal of urology.2004;11(2):2216-2219.
Schaeffer AJ, Montorsi F, Scattoni V, et al. Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate. BJU international.2007;100(1):51-57.
Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. The Journal of urology.2006;175(5):1605-1612.
Remzi M, Fong YK, Dobrovits M, et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. The Journal of urology.2005;174(4 Pt 1):1256-1260.
Chambo RC, Tsuji FH, de Oliveira Lima F, Yamamoto HA, de Jesus CM. What is the ideal core number for ultrasound-guided prostate biopsy? Korean journal of urology. 2014;55(11):725-731.
Walz J, Graefen M, Chun FK, et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. European urology.2006;50(3):498-505.
Pelzer AE, Bektic J, Berger AP, et al. Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the tyrol screening project. European urology. 2005;48(6):916-921.
Linzer DG, Stock RG, Stone NN, Ratnow R, Ianuzzi C, Unger P. Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer. Urology. Nov 1996;48(5):757-761.
Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. European urology.2013;64(6):876-892.
Scott S, Samaratunga H, Chabert C, Breckenridge M, Gianduzzo T. Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis. BJU international.2015.
Zigeuner R, Schips L, Lipsky K, et al. Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. Urology. 2003;62(5):883-887.
Escudero-Fontano E, Juan-Escudero J, Nuno de la Rosa-Garcia I, et al. Influence of learning curve in the diagnosis of prostate cancer by ultrasound guided biopsy. Archivos espanoles de urologia.2015;68(6):532-538.
Dell'Atti L. The best prostate biopsy scheme is dictated by the gland volume: a monocentric study. European review for medical and pharmacological sciences.2015;19(15):2739-2743.
Lovšin M. Sodobna diagnostika raka prostate. Onkologija. 2006;10(1):34-36.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
